S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   164.96 (-1.25%)
MSFT   399.36 (-1.21%)
META   483.88 (-3.57%)
GOOGL   153.97 (-1.31%)
AMZN   174.95 (-2.38%)
TSLA   148.99 (-0.63%)
NVDA   801.70 (-5.32%)
AMD   149.10 (-3.86%)
NIO   3.83 (-4.25%)
BABA   68.89 (+0.01%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.04 (-4.37%)
GE   149.12 (-2.50%)
CGC   8.09 (+3.32%)
DIS   112.09 (-0.30%)
AMC   3.23 (+10.62%)
PFE   25.79 (+1.58%)
PYPL   62.18 (+0.13%)
XOM   119.90 (+1.16%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   164.96 (-1.25%)
MSFT   399.36 (-1.21%)
META   483.88 (-3.57%)
GOOGL   153.97 (-1.31%)
AMZN   174.95 (-2.38%)
TSLA   148.99 (-0.63%)
NVDA   801.70 (-5.32%)
AMD   149.10 (-3.86%)
NIO   3.83 (-4.25%)
BABA   68.89 (+0.01%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.04 (-4.37%)
GE   149.12 (-2.50%)
CGC   8.09 (+3.32%)
DIS   112.09 (-0.30%)
AMC   3.23 (+10.62%)
PFE   25.79 (+1.58%)
PYPL   62.18 (+0.13%)
XOM   119.90 (+1.16%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   164.96 (-1.25%)
MSFT   399.36 (-1.21%)
META   483.88 (-3.57%)
GOOGL   153.97 (-1.31%)
AMZN   174.95 (-2.38%)
TSLA   148.99 (-0.63%)
NVDA   801.70 (-5.32%)
AMD   149.10 (-3.86%)
NIO   3.83 (-4.25%)
BABA   68.89 (+0.01%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.04 (-4.37%)
GE   149.12 (-2.50%)
CGC   8.09 (+3.32%)
DIS   112.09 (-0.30%)
AMC   3.23 (+10.62%)
PFE   25.79 (+1.58%)
PYPL   62.18 (+0.13%)
XOM   119.90 (+1.16%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   164.96 (-1.25%)
MSFT   399.36 (-1.21%)
META   483.88 (-3.57%)
GOOGL   153.97 (-1.31%)
AMZN   174.95 (-2.38%)
TSLA   148.99 (-0.63%)
NVDA   801.70 (-5.32%)
AMD   149.10 (-3.86%)
NIO   3.83 (-4.25%)
BABA   68.89 (+0.01%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.04 (-4.37%)
GE   149.12 (-2.50%)
CGC   8.09 (+3.32%)
DIS   112.09 (-0.30%)
AMC   3.23 (+10.62%)
PFE   25.79 (+1.58%)
PYPL   62.18 (+0.13%)
XOM   119.90 (+1.16%)
Free Trial

Silence Therapeutics (SLN) Earnings Date, Estimates & Call Transcripts

→ Start loving Mondays like this (From DTI) (Ad)
Free SLN Stock Alerts
$22.80
+0.78 (+3.54%)
(As of 01:38 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
May. 21Estimated
Actual EPS
(Mar. 13)
-$0.47 Missed By -$0.22
Consensus EPS
(Mar. 13)
-$0.25
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

SLN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SLN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Silence Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.46)($0.46)($0.46)
Q2 20241($0.53)($0.53)($0.53)
Q3 20241($0.53)($0.53)($0.53)
Q4 20241($0.65)($0.65)($0.65)
FY 20244($2.17)($2.17)($2.17)
Q1 20251($0.65)($0.65)($0.65)
Q2 20251($0.69)($0.69)($0.69)

SLN Earnings Date and Information

Silence Therapeutics last announced its earnings data on March 13th, 2024. The reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.22. The firm had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. Silence Therapeutics has generated ($1.46) earnings per share over the last year (($1.46) diluted earnings per share). Earnings for Silence Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.36) per share. Silence Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 21st, 2024 based off prior year's report dates.

Silence Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/21/2024
Estimated)		------- 
3/13/2024Q4 2023($0.25)($0.47)($0.22)($0.47)$11.46 million$2.61 million
11/14/2023Q3 2023($0.56)($0.28)+$0.28($0.28)$3.73 million$3.54 million
8/16/2023Q2 2023($0.59)($0.36)+$0.23($0.36)$1.94 million$11.40 million
5/16/2023Q1 2023($0.51)($0.35)+$0.16($0.35)$4.08 million$13.82 million
3/15/2023Q4 2022$0.45($0.46)($0.91)($0.46)$36.30 million$5.59 million
11/10/2022Q3 2022($0.60)($0.25)+$0.35($0.25)-$3.97 million
8/11/2022Q2 2022($0.60)($0.50)+$0.10($0.50)-$4.58 million
5/16/2022Q1 2022($0.62)($0.35)+$0.27($0.35)-$7.68 million
3/17/2022Q4 2021($0.62)($0.42)+$0.20($0.42)$2.74 million$4.60 million
11/16/2021Q3 2021-($0.46)($0.46)($0.46)-$4.35 million

Silence Therapeutics Earnings - Frequently Asked Questions

When is Silence Therapeutics's earnings date?

Silence Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 21st, 2024 based off last year's report dates. Learn more on SLN's earnings history.

Did Silence Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Silence Therapeutics (NASDAQ:SLN) missed the analysts' consensus estimate of ($0.25) by $0.22 with a reported earnings per share (EPS) of ($0.47). Learn more on analysts' earnings estimate vs. SLN's actual earnings.

How much revenue does Silence Therapeutics generate each year?

Silence Therapeutics (NASDAQ:SLN) has a recorded annual revenue of $31.55 million.

How much profit does Silence Therapeutics generate each year?

Silence Therapeutics (NASDAQ:SLN) has a recorded net income of -$53.82 million. SLN has generated -$1.46 earnings per share over the last four quarters.

What is Silence Therapeutics's EPS forecast for next year?

Silence Therapeutics's earnings are expected to grow from ($1.38) per share to ($1.36) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:SLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes